Type 2 Diabetes Overview
Type 2 Diabetes Overview
Type 2 diabetes is a long-term condition in which blood glucose sits above the range the body normally holds it in — because the cells answer insulin less well than they should, and because the pancreas, over years, cannot make enough to overcome that. It is found by a blood test far more often than by a symptom. Almost everything that follows comes out of that: the number and the risk run on different timelines, the target is set for a person, and low glucose is something treatment does rather than the disease.
-
Often silent
it can be present for years without symptoms — most diagnoses come from a blood test, not from feeling unwell
-
Two timelines
the number answers in weeks, complication risk is built over years. Lowering risk is the aim, not the lowest number
-
Targets are individual
an agreed HbA1c target is written down for you, and it is loosened rather than tightened where lows or frailty make tight control unsafe
-
Five subspecialties
our endocrinology department covers diabetes, thyroid disease, obesity and metabolic disease, pituitary, adrenal and gonadal disease, and bone metabolism
What type 2 diabetes is — resistance first, shortage later
Type 2 diabetes is a long-term condition in which blood glucose sits above the range the body normally holds it in, produced by two things in sequence rather than at once. The first is insulin resistance: the cells of muscle, liver and fat stop answering insulin as readily, so glucose stays in the bloodstream. The second is that the pancreas makes more insulin, and can hold glucose in the ordinary range for years by doing so. The diagnosis is made when that compensation no longer keeps up.
This is what separates it from type 1 diabetes, where the insulin-producing cells are destroyed and insulin falls to almost nothing. In type 2 diabetes insulin is present, and early on often in larger amounts than normal — the signal is not missing, the tissue receiving it has stopped listening. The distinction decides what the medicine is for and when insulin enters the plan, and it is set out further on the type 1 diabetes page.
Because resistance builds slowly and compensation holds for years, there is no moment when the condition begins. That is why most people have no symptoms when it is found, and why some of the damage has already begun: years of exposure to higher glucose are what harm the small vessels of the eyes, kidneys and nerves and add to the risk carried by the larger vessels.
| What is happening | What it explains |
|---|---|
| Insulin resistance — cells answer insulin less well than they should | Why insulin is present but does less, and why the pancreas has to produce more of it to hold glucose at the same level |
| A pancreas that compensates, and then cannot | Why glucose stays normal for years and then drifts up, with no onset to point at and no symptom to date it from |
| Beta-cell function declining across the years | Why treatment usually becomes more rather than less over time, and why review has to be continuous rather than occasional |
| Years of exposure to glucose above the normal range | Why complications are silent and cumulative, and why the number matters for risk rather than for how a person feels today |
It is not caused by eating sugar on its own, and it is not a personal failure: the strongest drivers are inherited, arrive with age, and depend on where fat is carried. Nor is it simply present or absent — beneath the diagnostic threshold lies a range in which risk is already raised.
The numbers: what is measured, and what each one is for
Diabetes is described in numbers more than most conditions, and the numbers are not interchangeable. Each answers a different question, and treating them as versions of the same thing is how people end up reassured or alarmed by the wrong figure.
| Measurement | What it reflects | What it is used for |
|---|---|---|
| HbA1c | The proportion of haemoglobin carrying glucose, which follows average glucose across the preceding two to three months | Diagnosis, and the number most targets are written against. It hides swings and lows |
| Fasting plasma glucose | One point in time, taken after eight hours without food | Diagnosis. It says nothing about what happens after a meal, which is where the day is mostly spent |
| Two-hour value during a glucose tolerance test | How the body handles a measured glucose load | Diagnosis where the other two are inconclusive, and the test used in pregnancy |
| Self-measured glucose | A single reading, taken by the person, at a moment they chose | Pattern-finding, and the only way to know what a particular meal, walk or illness did |
| Continuous or flash glucose monitoring | Glucose across the whole day and night, including the hours nobody measures by finger-prick | Showing direction, swings and overnight lows — things an average cannot show at all |
| Blood pressure, lipids, kidney and eye results | The other risks that travel with the condition | Where most of the long-term risk sits, and where treatment often does more than glucose lowering |
Two cautions about HbA1c, since it is the figure most people are given and least often explained. It is a proportion, not an average in the units a meter shows, and it should not be converted into one. And it depends on red cells living a normal lifespan, so it cannot be used where red cell turnover is abnormal — anaemia, haemoglobin variants, pregnancy, recent transfusion, advanced kidney disease — and glucose measurements take its place.
Pattern is what an average loses: two people with the same HbA1c can have entirely different days. Flash continuous glucose scanning is used in our endocrinology department to make that visible, and it usually changes the plan more than the average does. What each figure means for diagnosis is on the diagnosis page.
Targets are individual — lower is not automatically better
The commonest misunderstanding about this condition is that the aim is the lowest number obtainable. It is not: the aim is the level at which complication risk falls without exposing the person to harm, and where those pull apart, the target moves.
The reason is that the two sides run on different clocks. The benefit of a lower number accrues over years, because that is how long the vascular damage takes. The harm of driving it too low is immediate: hypoglycaemia, and in older people the falls and confusion that come with it. Where there are decades ahead and no cardiovascular disease, waiting for the benefit is a fair trade and the target is set tighter. Where there are not, or where lows are already happening, it is not.
| The situation | Which way the target moves |
|---|---|
| Young, recently diagnosed, no cardiovascular disease, long life expectancy | Tighter — there are decades for the benefit to accumulate, and little to lose meanwhile |
| Long duration, established heart or kidney disease | Set around the whole picture — the medicine choice matters as much as the number |
| Older, frail, or living with several long-term conditions | Looser — avoiding hypoglycaemia and its consequences outweighs the marginal gain from a lower figure |
| Repeated hypoglycaemia, or reduced awareness of lows | Loosened immediately and the regimen reviewed; awareness recovers when lows stop |
In practice a target is agreed, written down and revisited when circumstances change — after an illness, when a medicine is added or stopped, with a change in weight or kidney function, before a pregnancy, and as a person grows older. A loosened target is not an abandoned one: it is the same reasoning applied to a different person. The reasoning continues on the treatment page.
It also explains a decision people find puzzling: a medicine may be chosen for its effect on the heart or the kidney rather than on HbA1c, and the number may then barely move. The number marks one risk; it is not the score.
The shape of treatment: what is used, and why
Treatment has a foundation and then layers, and the foundation is not a medicine: structured education, food and activity a person can live with, weight, sleep, not smoking, and blood pressure and lipids treated to agreed targets. Medicine is added to that foundation; it does not replace it.
Metformin is the usual first medicine and has held that place for a long time: it reduces the glucose the liver releases, improves how well insulin works, does not cause hypoglycaemia on its own and does not cause weight gain. It is started low and built up, because the stomach side effects that put people off it are largely avoided that way. Whether it suits a person and at what dose is a clinical judgement taking kidney function into account.
| Class | What it does | Why it is chosen |
|---|---|---|
| Metformin | Reduces glucose released by the liver and improves insulin sensitivity | First-line, long experience, no hypoglycaemia on its own, weight-neutral |
| SGLT2 inhibitors | Let the kidney pass glucose out in the urine | Chosen for heart and kidney protection as a class, not only for the glucose effect |
| GLP-1 receptor agonists | Increase insulin when glucose is high, slow the stomach, reduce appetite | Chosen for glucose and weight together, and for cardiovascular benefit as a class where vascular disease is established |
| Sulfonylureas | Stimulate the pancreas to release more insulin | Effective and long-established, but they cause hypoglycaemia and weight gain, which is the trade-off |
| Insulin | Replaces what the body no longer makes enough of | Used when beta-cell output is no longer sufficient — a stage of the condition, not a verdict on it |
The choice between those classes is not made by how high the number is. It is made by the picture: whether heart or kidney protection should weigh heavily, what the weight is doing, how much hypoglycaemia risk is acceptable, and what is available where the person lives. Suitability, availability and dose are assessed by the clinician; this page names classes and reasons, not prescriptions.
And it has to be said in the same breath: hypoglycaemia comes from treatment, not from the disease. Metformin, GLP-1 receptor agonists and SGLT2 inhibitors, used alone, carry little risk of it. Insulin and sulfonylureas do, and anyone taking either needs the recognition and treatment of a low written into the plan — covered in detail on the treatment page.
What a full assessment contains
An assessment has three jobs: establish the diagnosis properly, establish whether the type really is type 2, and record what the years before diagnosis have left in the eyes, kidneys and feet. A consultation producing a prescription without those has skipped most of what makes it right.
| Assessment | The question it answers |
|---|---|
| HbA1c, with fasting glucose or a tolerance test where HbA1c cannot be used | Is the diagnosis established, and on what? An abnormal result without symptoms is repeated, not acted on |
| Autoantibodies and C-peptide, where the picture is not typical | Is this really type 2, or a slowly progressing form of type 1? Getting it wrong changes the treatment |
| Urine albumin-to-creatinine ratio and estimated filtration rate | What do the kidneys look like at the start, and is albumin leaking that treatment should address? |
| Dilated eye examination with retinal imaging | Is retinopathy already present? It is silent until it is not, and treatable when found early |
| Foot examination — sensation, vibration and pulses | Has sensation been lost, and is the blood supply adequate? Both set how often feet are checked |
| Blood pressure, lipids, liver, weight and waist | Where is the rest of the risk, and what needs treating alongside glucose? |
| Thyroid function, where there is a reason to look | Thyroid disease clusters with diabetes, and our endocrinology department holds a thyroid subspecialty |
| A review of every other medicine, including anything bought over the counter | Is something else raising glucose — a corticosteroid above all — or likely to interact? |
| Continuous or flash glucose monitoring for a period | What is the pattern, overnight and after meals? The part an average cannot show |
Within our hospital this is carried out by the endocrinology department, whose diabetes subspecialty sits alongside thyroid disease, obesity and metabolic disease, pituitary, adrenal and gonadal disease, and bone metabolism. It holds a fundus screening device, a diabetic foot screening device, a lipid analyser, ultrasound, flash continuous glucose scanning and Medtronic insulin pumps, and performs thyroid nodule aspiration where a nodule needs characterising early.
The complications themselves have their own pages, and this guide points to them rather than repeating them: diabetic nephropathy, diabetic retinopathy and diabetic foot ulcers. What belongs here is the schedule on which they are looked for, set out on the monitoring page.
Why patients come to China for type 2 diabetes care
What international patients come for is almost never a medicine unavailable at home — the classes used here are used everywhere. It is the assembly, and assembly is where the years get lost: a diagnosis confirmed rather than assumed, the type established rather than inherited from a label, the eyes, kidneys and feet screened on a schedule, a target agreed and written down, and medicine chosen for the heart and kidney picture rather than the number alone.
Our hospital is a Class A tertiary general hospital with more than sixty years behind it. Its endocrinology department carries five subspecialties — diabetes, thyroid disease, obesity and metabolic disease, pituitary, adrenal and gonadal disease, and bone metabolism — and holds Medtronic insulin pumps, flash continuous glucose scanning, ultrasound, a lipid analyser, a fundus screening device and a diabetic foot screening device. Its published work on preventing complications in people with combined diabetes and obesity includes early coronary screening, multidisciplinary lower-limb arterial intervention for diabetic foot disease, and systematic treatment of diabetic retinopathy with our ophthalmologists. A medical weight-loss clinic builds programmes from an endocrine and metabolic standpoint, with attention to reducing the chance of regaining weight. Its named specialists include Dr Jiang Yiwen, chief physician, whose published interests cover thyroid disease and diabetes with its complications, and Dr Li Meng, whose interests include the acute and chronic complications of diabetes, thyroid disease, secondary hypertension, hyperuricaemia, gouty arthritis, adrenal and pituitary disease, and obesity.
Our hospital's traditional Chinese medicine department has been in place since the hospital was founded, and our Guoyi Hall is where senior physicians recognised at national and Guangdong provincial level see patients. Integrated Chinese and Western medicine is a designated specialty in Chancheng district; acupuncture and tuina there include traditional tendon-regulating and Qing-dynasty bone-setting methods, and one-finger Zen tuina is national intangible cultural heritage. Where a patient wants a combined approach, it is an addition to the treatment rather than a substitute, the measurements continue unchanged so any effect is visible rather than assumed, and anything taken has to be declared to the clinician managing the diabetes, because herbs and supplements can interact with prescribed medicines.
Most of the assessment can be established before travel. Sending HbA1c results with dates, current medicines with doses, kidney and lipid results, the last eye and foot screening reports and any monitoring downloads lets a clinician say whether the diagnosis is secure and which screening is overdue. That review is free and comes back before payment is discussed; what to send is on the practical questions page.